00:41 , Feb 9, 2018 |  BC Innovations  |  Product R&D

R is for readout

While AstraZeneca plc gets credit for transparency in publishing its metrics on R&D productivity, the data cover well-established targets addressed by conventional modalities. The more telling test for its “5R framework” will be whether it...
08:00 , Jan 29, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: 5-lipoxygenase activating protein (FLAP; ALOX5AP)

Inflammation INDICATION: Inflammation Studies in vitro and in whole blood identified a new FLAP inhibitor that could help treat inflammation. Chemical synthesis and in vitro screening identified a lead compound called AZD6642 that inhibited FLAP binding activity...
07:00 , Aug 1, 2011 |  BioCentury  |  Strategy

Therapeutically adjacent

Bristol-Myers Squibb Co.'s acquisition of Amira Pharmaceuticals Inc. appears at first blush to net a single compound that has completed Phase I testing in a completely new disease area for the pharma, along with some...
08:00 , Feb 10, 2011 |  BC Innovations  |  Targets & Mechanisms

Getting a GRP on asthma

Researchers at the Duke University School of Medicine have shown thata small molecule blocker of gastrin-releasing peptide, originally identified as a tumor growth inhibitor by researchers at the National Cancer Institute, attenuates multiple parameters of...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Company News

Amira sales and marketing update

Amira will restructure and reduce headcount by about 25 (50%) to 25 in order to focus on early- to mid-stage clinical research. The cuts will come from discovery research and administrative support. CSO and co-founder...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Company News

Amira, GlaxoSmithKline deal

Amira received an undisclosed milestone payment from GlaxoSmithKline under a 2008 deal that granted the pharma exclusive, worldwide rights to Amira's 5-Lipoxygenase Activating Protein ( FLAP) inhibitors. The milestone was triggered by the development...
07:00 , Aug 3, 2009 |  BioCentury  |  Strategy

Questions of the heart

On its way to becoming a bellwether biotech, Gilead Sciences Inc. saw its market cap jump some 50% in less than two years, climbing from about $26 billion in early 2006 to about $40 billion...
07:00 , Aug 3, 2009 |  BioCentury  |  Strategy

What might fit

What might fit Company Product Description Indication Status Arca biopharma Inc. (NASDAQ:ABIO) Gencaro bucindolol Non-selective beta blocker Chronic heart failure FDA complete response letter...
07:00 , Jul 6, 2009 |  BioCentury  |  Product Development

Amira's lipid love affair

Spurred by academic research linking LPA1 to idiopathic pulmonary fibrosis, Amira Pharmaceuticals Inc. used its medicinal chemistry expertise in bioactive lipids to design antagonists for preclinical studies. The company presented proof-of-concept data in a mouse...
07:00 , May 28, 2009 |  BC Innovations  |  Targets & Mechanisms

New angiogenesis targets

An international collaboration among researchers at the Karolinska Institute, Discovery Genomics Inc. and AngioGenetics AB has produced a set of previously unknown and potentially druggable targets in angiogenesis along with several matching antiangiogenic compounds.1 AngioGenetics was...